“The existing circumstance has exposed some structural weaknesses during the EU’s medicines provide chain in addition to a high dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides claimed. She advisable that offer chain problems be tackled in an EU pharmaceutical system predicted to get introduced by the top of the